Form 4: Sage Therapeutics Executive Gregory Shiferman Receives Stock Options and Restricted Stock Units

Gregory Shiferman, a Senior Vice President at Sage Therapeutics, was granted stock options and restricted stock units (RSUs) under the company's 2024 Equity Incentive Plan.

Summary

• Gregory L. Shiferman, a Senior Vice President at Sage Therapeutics, received 5,000 restricted stock units (RSUs) and options to purchase 10,000 shares of common stock on November 1, 2024.
• The RSUs vest in equal annual installments over four years, starting November 1, 2025, contingent upon continued service.
• The stock options, with an exercise price of $6.05, also vest over four years, with 25% vesting on November 1, 2025, and the remainder in equal monthly installments thereafter, subject to continued service.
• Following these transactions, Shiferman directly owns 19,967 shares of Sage Therapeutics common stock and options to purchase 10,000 shares.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. The sentiment is neutral to positive as it suggests confidence in the company's future.

Positives

• The grant of RSUs and stock options aligns Shiferman's interests with those of the shareholders, incentivizing him to contribute to the company's long-term success.
• The vesting schedules encourage continued service and commitment from Shiferman.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the equity grants suggest an expectation of continued growth and success.

Industry Context

Equity grants are a common practice in the biotechnology industry to attract, retain, and incentivize key executives. The terms of the grants, such as vesting schedules, are typically designed to align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation components for executives in publicly traded biotech companies like Sage Therapeutics.
• Vesting schedules of four years with annual or monthly installments are also typical in the industry, similar to companies like Biogen, Vertex Pharmaceuticals, and Amgen.
• The specific number of shares and exercise price would be determined by factors such as the executive's role, performance, and the company's overall compensation strategy.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align management's interests with the company's long-term success.
• Employees may be motivated by the potential for similar equity grants in the future.

Key Dates